Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2026-01-20 00:00:00 ET · period of report 2026-01-12 · accession 0001193125-26-016651 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-01-20 | 2026-01-12 | TYRA | Bensen Daniel | Chief Discovery Off | S - Sale | $28.52 | -8,000 | 155.0K | -5% | -$228.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | S | D | 6,983 | $28.44 | 155,998 | D | — | — | (F2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
| 2 | Common | Common Stock | 2026-01-12 | S | D | 1,017 | $29.08 | 154,981 | D | — | — | (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |